{"id":"W3087827200","doi":"10.1016/j.annonc.2020.08.431","title":"329P Ribociclib (RIB) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and resistance to prior endocrine therapy (ET) in the MONALEESA (ML) -3 and -7 trials","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Internal medicine; Fulvestrant; Breast cancer; Hazard ratio; Goserelin; Placebo; Progression-free survival; Cancer; Surgery; Gastroenterology; Oncology; Tamoxifen; Chemotherapy; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006689984,0.0004522499,0.0007391463,0.0002058193,0.0001821268,0.0006575794,0.0002661437,0.000514211,0.005294035],"category_scores_gemma":[0.0007146336,0.0001700838,0.0008200607,0.0003231684,0.0002911834,0.0004877297,0.0003194578,0.001788197,0.001087027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005104175,"about_ca_system_score_gemma":0.0005057949,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007598588,"about_ca_topic_score_gemma":0.004425898,"domain_scores_codex":[0.9998199,0.00009077056,0.00001106349,0.00002235653,0.00001643892,0.00003948332],"domain_scores_gemma":[0.999853,0.00003422501,0.00002701703,0.00001126671,0.00001207189,0.000062368],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.4770575,0.003457809,0.01160579,0.003435546,0.003864261,0.0004799773,0.0002402872,0.004019399,0.02095696,0.002141462,0.02206559,0.4506755],"study_design_scores_gemma":[0.5968058,0.203206,0.07337137,0.001392469,0.006133164,0.003290344,0.0004796367,0.005490128,0.007954648,0.004957758,0.09680355,0.0001151988],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.920298,0.04513214,0.0007037294,0.003189352,0.0005221853,0.0008275567,0.003404456,0.0002550059,0.02566757],"genre_scores_gemma":[0.9753906,0.01193296,0.0007145203,0.001603591,0.000166547,0.0004029493,0.003621857,0.00002773623,0.00613925],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.005294035,"threshold_uncertainty_score":0.01771027,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07957722803001016,"score_gpt":0.4040811847777209,"score_spread":0.3245039567477107,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}